Cozart Brittany, Diaz Vera Jesus, Denham James D, Whiting William L
University of South Florida College of Medicine and.
Clin Neuropharmacol. 2018 May/Jun;41(3):103-105. doi: 10.1097/WNF.0000000000000277.
The mitochondrial cytopathies are a heterogeneous group of diseases characterized by heteroplasmic maternal transmission and selective dysfunction of tissues and organs highly dependent on aerobic respiration (eg, skeletal muscle, cardiac muscle, and brain). Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) is a specific subtype of mitochondrial cytopathy that is commonly associated with mood disturbances in individuals who survive until adulthood. Because of the altered cellular metabolism inherent in MELAS, it is often difficult to determine drug dosing, drug choice, and treatment response in patients with this rare disease. Historically, management of these patients focused on symptomatic relief and supplementation of compounds thought to optimize aerobic respiration (specifically, enzyme Co-Q10). We report a case in which an adult patient with MELAS and comorbid major depressive disorder demonstrated excellent response to the selective serotonin-norepinephrine reuptake inhibitor medication duloxetine.
线粒体细胞病是一组异质性疾病,其特征为异质性母系遗传以及对有氧呼吸高度依赖的组织和器官(如骨骼肌、心肌和脑)的选择性功能障碍。伴有乳酸性酸中毒和卒中样发作的线粒体脑肌病(MELAS)是线粒体细胞病的一种特定亚型,在存活至成年的个体中通常与情绪障碍相关。由于MELAS固有的细胞代谢改变,对于这种罕见病患者,往往难以确定药物剂量、药物选择和治疗反应。从历史上看,这些患者的管理主要集中在症状缓解以及补充被认为可优化有氧呼吸的化合物(特别是辅酶Q10)。我们报告了一例患有MELAS和共病重度抑郁症的成年患者,该患者对选择性5-羟色胺-去甲肾上腺素再摄取抑制剂药物度洛西汀表现出极佳反应。